Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 15/20 | 0.51 |
| ▸ | BCHE | P06276 | 13/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2026891 | 0.93 | ACHE (0.57) | ACHEBCHEFAAHMARK4ALOX5 | |
| SCHEMBL2799811 | 0.93 | ACHE (0.57) | ACHEBCHEFAAHMARK4ALOX5 | |
| SCHEMBL2026893 | 0.93 | ACHE (0.57) | ACHEBCHEFAAHMARK4ALOX5 | |
| SCHEMBL2800774 | 0.91 | CA1 (0.39) | ACHEBCHEFAAH | |
| SCHEMBL2025338 | 0.91 | CA1 (0.39) | ACHEBCHEFAAH | |
| SCHEMBL2053885 | 0.91 | CA1 (0.39) | ACHEBCHEFAAH | |
| SCHEMBL1825973 | 0.79 | CA1 (0.39) | ACHEBCHE | |
| SCHEMBL1826052 | 0.75 | CYP19A1 (0.36) | ACHE | |
| SCHEMBL16726991 | 0.74 | SLC6A4 (0.43) | — | |
| SCHEMBL1826835 | 0.74 | ACHE (0.40) | ACHEBCHEFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637713-B2 | Process for preparation of optically active compounds using transfer hydrogenation | NOVARTIS AG (CH) | 2014-01-28 | — | — | US | disclosed |
| US-20130096337-A1 | Process for Preparation of Optically Active Compounds using Transfer Hydrogenation | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-8415508-B2 | Process for the preparation of optically active compounds using transfer hydrogenation | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | disclosed |
| US-20100168229-A1 | Process for the preparation of optically active compounds using transfer hydrogenation | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096337-A1 | Process for Preparation of Optically Active Compounds using Transfer Hydrogenation | SPR, ACHE, QDPR | ACHE 2/4885BCHE 34/4885FAAH 816/4885 |
| US-20100168229-A1 | Process for the preparation of optically active compounds using transfer hydrogenation | SPR, ACHE, QDPR | ACHE 2/4885BCHE 33/4885FAAH 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.